Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revive Therapeutics Ltd. C.RVV

Alternate Symbol(s):  RVVTF

Healthcare
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is... see more

Recent & Breaking News (CSE:RVV)

Revive (CSE:RVV) advancing COVID-19 drug

Caroline Egan  June 24, 2022

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire June 24, 2022

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire June 6, 2022

Revive Therapeutics Advances Inflammatory Liver Disorders Programs for Autoimmune Hepatitis and Liver Transplantation

GlobeNewswire May 31, 2022

Revive (CSE:RVV) gets FDA OK for Bucillamine trials to treat COVID-19

Caroline Egan  May 26, 2022

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire May 26, 2022

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire May 16, 2022

PharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business Highlights and Update

GlobeNewswire April 25, 2022

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire April 25, 2022

Revive Therapeutics (CSE:RVV) confirms effectiveness of Bucillamine

Caroline Egan  April 18, 2022

Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19

GlobeNewswire April 18, 2022

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire April 11, 2022

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire March 29, 2022

HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical Research

GlobeNewswire February 24, 2022

Revive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation

GlobeNewswire February 15, 2022

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire February 14, 2022

The StockTalk Cannabis Report: Jan 21, 2022

Dave Jackson January 21, 2022

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire January 18, 2022

Revive Therapeutics provides update of psilocybin pharma programs

Stockhouse Editorial January 17, 2022

Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs

GlobeNewswire January 17, 2022